The present-day vaccine manufacturing
sector has undergone several changes. The demand for human vaccination is
anticipated to shoot up – especially in the underdeveloped and developing parts
of the world. The emerging countries require affordable vaccines. Only a small portion of a large
population of an underdeveloped country has access to high-quality heat stable vaccines. It’s predicted
that by circa 2015, the entire vaccine market will be worth USD 25 billion.
Vaccine development in the Asia Pacific Region
Many vaccine researchers as well as manufacturers
have taken note of low immunization rates in Asia Pacific regions. The regions have
three things in common: burgeoning population, increased personal wealth and
enhanced govt. funding. Each of these factors contributes to improving personal
health of the population. Vaccine growth in Asia Pacific is up to 65 percent.
New approaches
Increased demands for vaccination have
put new challenges for vaccinologists and researchers. As the market grows,
fresh, innovative approaches are developed to build effective vaccines. Health
policy makers are leaving no stone unturned to make vaccines easily accessible.
The policy makers adopt a large set of
improved technologies for making vaccines easily available.
Accelerated sterility testing – One of
the most significant approaches that are adopted by contemporary vaccinologists
is improved sterility testing. The main purpose of accelerated sterility
testing is providing biosafety to a vaccine. In simple terms, the test helps
determine whether a vaccine has fungi/bacteria or not. Accelerated sterility
testing helps vaccinologists perform quick checks upon a vaccine and saves a
lot of time.
Real-time detection – The absence or
presence of mycoplasma can now be analysed via RNA detection. The RNA detection
uses new types of kits and technologies. Such revolutionary detection kits
require a meagre (20 ml) of test article.
No comments:
Post a Comment